The English University of Oxford reported this Saturday that it will resume its clinical trials of the COVID-19 vaccine, after being recently interrupted after a volunteer in the United Kingdom suffered an adverse reaction. In a statement, Oxford indicated that the tests of the vaccine, called ChAdOx1 nCoV-19 and that it is developed together with the pharmaceutical AstraZeneca, will resume in the UK after pausing on the 6th as a precautionary measure.
This possible vaccine, considered one of the most advanced developed worldwide, is in the final stages of clinical trials before receiving authorization from regulatory bodies to proceed with immunizing the population.
At the end of August, the EU closed a ‘first contract’ with the British pharmaceutical company AstraZeneca guaranteed access to 300 million doses of the vaccineTherefore, the suspension of the trials was a serious concern in Europe and around the world.
In its note to account for the resumption of testing, the university indicated that around the world some 18,000 people have received this study vaccine as part of clinical trials and that, in tests as extensive as this, it is expected that some participant may feel bad. “Each case must be carefully evaluated to ensure the safety of the vaccine,” added the aforementioned text, which has not specified the date of resumption of the trials. Clinical trials in the UK will start again after the independent review process has been completed.
“We cannot reveal the medical information about the disease (of the volunteer) for reasons of confidentiality of the participant”, explains the high house of study in its note. “We are committed,” he added, “to the safety of our participants and the highest level of conduct in our studies and we will closely monitor the safety” of the vaccine.
The potential vaccine, which gave promising results in early trials, was undergoing clinical trials in the United Kingdom, the United States, Brazil and South Africa.
Last month, the Governments of Argentina and Mexico, as well as the Mexican Slim Foundation, reached an agreement with AstraZeneca and the University of Oxford to manufacture the vaccine for their countries and then distribute it to the rest of Latin America, except Brazil.
The president of Argentina, Alberto Fernández, reported in August that the goal was to produce between 150 and 250 million doses that would be available at affordable prices, with an individual cost of between 3 and 4 dollars.